-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price Target

Benzinga·07/07/2026 16:57:33
Listen to the news
BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintains $15 price target.